Collaboration will add a new multigene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness CAMBRIDGE, MA USA and COLUMBIA, MD, March […]
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months After stopping the 12-month immune suppression regimen, assessment of 18-month data shows evidence of sustained cell engraftment […]
First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021 Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in […]
This press release was updated on October 2, 2023. Specifically, two data points have been updated after it was discovered that the data point from the Hauser diary OFF time in the low dose cohort and the data point from the MDS-UPDRS Part III low […]
Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio’s […]
Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment Phase II clinical study expected to begin enrolling patients in H1 […]
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities Acceleration of the development of cell therapies in BlueRock’s pipeline, with initial focus on the ongoing BRT-DA01 clinical trial in Parkinson’s disease Berlin, June 8, 2022 – Bayer AG announced […]
CAMBRIDGE, Mass., January 18, 2022 – BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived […]
CAMBRIDGE, Mass., January 6, 2022 – BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s […]
CAMBRIDGE, Mass., July 19, 2021 — BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem […]
